The information on this section of the website about treatment with Saxenda® (liraglutide injection 3mg) for weight loss in addition to diet and exercise is intended for UK healthcare professionals. If you are a member of the public or a patient, please visit the relevant section:

Saxenda®(liraglutide injection 3mg) overview

scroll

What is Saxenda® used for?

Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of:

  • ≥30 kg/m² (obese); or
  • ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.1

Treatment with Saxenda® should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.1

This website offers some further information to help you better understand Saxenda®.

Saxenda® (liraglutide) pack with pen
Icon of human side profile with brain showing

How Saxenda® works

Saxenda® contains the active substance liraglutide which works by acting on receptors in the brain that control appetite. The exact mechanism of action is not entirely clear.1

Learn more

Efficacy icon – Two arrows pointing upwards and downwards

Saxenda® efficacy

The clinical efficacy of Saxenda® has been assessed in a number of clinical trials.
Learn more

Saxenda® (liraglutide) safety information icon depicting heart with band aid

Saxenda® safety information1,2

Since its introduction, over one million patients with obesity have been prescribed Saxenda®. As with all medications, Saxenda® may cause side effects, although not everyone will experience them.

Learn more

Full-length image of middle-aged male doctor standing with hand in white lab coat pocket and stethoscope around his neck
Getting started on Saxenda® (liraglutide) icon depicting check mark

Getting your patients started on Saxenda®

Saxenda® is a once-daily glucagon-like peptide-1 (GLP-1) analogue indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients.

Learn more

Saxenda® availability on the NHS

Saxenda® has been recommended by NICE as a cost-effective treatment for use in the NHS for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity, in certain adults.3

Learn more

Icon of SmPC

Summary of Product Characteristics (SMPC)

For an overview of the Summary of Product Characteristics for Saxenda® click below.

Summary of Product Characteristics

Icon of prescription information

Prescribing Information

For an overview of the Saxenda® Prescribing Information click below.

Prescribing Information

Reporting side effects icon depicting exclamation mark

Reporting of side effects

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.

Report an Adverse Event

If you would like to request a visit from a representative please contact us on [email protected].

For all product related enquiries please contact us via our online information request form at www.novonordisk.co.uk

References:

  1. Saxenda® Summary of Product Characteristics
  2. le Roux CW, Astrup A, Fujioka K,et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-1409
  3. NICE. Liraglutide for managing overweight and obesity. Available at: https://www.nice.org.uk/guidance/indevelopment/gid-ta10388 [Last accessed: 12 November 2020]
back to top

This website contains information about Saxenda®(liraglutide injection 3mg) suitable for HCPs and patients.

This website provides a range of useful information about Saxenda®. This information has been tailored to meet your needs, so please tell us whether you are:

UK healthcare professional icon

A UK healthcare professional

Learn more

UK patient icon

A person who has been prescribed Saxenda® in the UK

Learn more

UK member of the public icon

A UK member of the public

Learn more